Amgen Shares Fall on Weight-Loss Drug Tummy Troubles - Barron's
1. Amgen shares fell 6% after a weight-loss trial's disappointing results. 2. High dropout rates were reported due to gastrointestinal side effects. 3. MariTide is designed to be injected monthly, unlike competitors’ weekly options. 4. Phase 3 trials aim to reduce dropouts by ramping up doses slowly. 5. Average weight loss among patients was between 12% and 19.9%.